Pembrolizumab autoimmune related diabetes: Moving forward, keep learning

doi:10.5306/wjco.v15.i5.576

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (440)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

317

Sum=325

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=90

Publishing Process of This Article

Item

Count

Browse

Download

Sum=6

May 24, 2024 (publication date) through Jun 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. May 24, 2024; 15(5): 576-579
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.576

Pembrolizumab autoimmune related diabetes: Moving forward, keep learning

Jose Angel Garcia, Diego Alcaraz, Esther Holgado, Felipe Couñago

Jose Angel Garcia, Diego Alcaraz, Department of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Madrid 28002, Spain

Esther Holgado, Department of Chief of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Madrid 28002, Spain

Felipe Couñago, Department of Chief of Radiation Oncology, Genesiscare-San Francisco de Asis University Hospital, Madrid 28002, Spain

Felipe Couñago, Department of Chief of Radiation Oncology, GenesisCare-Vithas La Milagrosa Hospital, Madrid 28010, Spain

Author contributions: Garcia JA, Alcaraz D, Holgado E and Couñago F contributed equally to this work; Garcia JA, Alcaraz D, Holgado E and Couñago F wrote the manuscript; All authors have read and approve the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jose Angel Garcia, MMed, Attending Doctor, Department of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Joaquin Costa 28, Madrid 28002, Spain. jose.garcia@genesiscare.es

Received: November 30, 2023
Revised: February 25, 2024
Accepted: April 8, 2024
Published online: May 24, 2024

Core Tip

Core Tip: Pembrolizumab-induced type 1 diabetes mellitus is a rare and potentially serious adverse event of immunotherapy, with a significant number of cases debuting abruptly and in a state of diabetic ketoacidosis without clear predisposing factors. Further research and strict follow-up by oncologists are fundamental tools for prevention and early treatment focusing on reducing the morbidity and mortality associated with this side effect.